Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics to Bolster Rare Liver Disease Pipeline
“Mirum Pharmaceuticals has finalized its acquisition of Bluejay Therapeutics in a deal valued at up to $820 million, incorporating the late-stage asset brelovitug into its portfolio for treating chronic hepatitis delta virus; the move expands Mirum’s expertise in rare liver disorders, with Phase 3 trial data anticipated in the latter half of 2026 and potential … Read more